Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 9
2009 12
2010 12
2011 18
2012 27
2013 12
2014 18
2015 16
2016 15
2017 15
2018 16
2019 4
2020 18
2021 44
2022 26
2023 18
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Results by year

Filters applied: . Clear all
Page 1
Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD, Yalamanoglu A, Boyman O. Arnold DD, et al. Front Immunol. 2022 Jul 6;13:888392. doi: 10.3389/fimmu.2022.888392. eCollection 2022. Front Immunol. 2022. PMID: 35874710 Free PMC article.
Currently, three IL-1 blockers are approved, namely anakinra, canakinumab and rilonacept, and two additional ones are expected to receive approval, namely gevokizumab and bermekimab. ...Contrarily, Rilonacept did not reach superiority compared to placebo in the trea …
Currently, three IL-1 blockers are approved, namely anakinra, canakinumab and rilonacept, and two additional ones are expected to rec …
Treating inflammation by blocking interleukin-1 in humans.
Dinarello CA, van der Meer JW. Dinarello CA, et al. Semin Immunol. 2013 Dec 15;25(6):469-84. doi: 10.1016/j.smim.2013.10.008. Epub 2013 Nov 23. Semin Immunol. 2013. PMID: 24275598 Free PMC article. Review.
Three IL-1blockers have been approved: the IL-1 receptor antagonist, anakinra, blocks the IL-1 receptor and therefore reduces the activity of IL-1alpha and IL-1beta. A soluble decoy receptor, rilonacept, and a neutralizing monoclonal anti-interleukin-1beta antibody, canaki …
Three IL-1blockers have been approved: the IL-1 receptor antagonist, anakinra, blocks the IL-1 receptor and therefore reduces the activity o …
Rilonacept.
[No authors listed] [No authors listed] 2020 Apr 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2020 Apr 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643801 Free Books & Documents. Review.
Rilonacept is a recombinant interleukin-1 (IL-1) antagonist which is used in the therapy of cryopyrin-associated periodic syndromes (CAPS) and other autoinflammatory conditions. Rilonacept has had limited clinical use and has yet to be linked to cases of clinically …
Rilonacept is a recombinant interleukin-1 (IL-1) antagonist which is used in the therapy of cryopyrin-associated periodic syndromes ( …
Rilonacept for the treatment of recurrent pericarditis.
Fava AM, Reyaldeen R, Lo Presti S, Goyal A, Akintoye E, Hughes D, Klein AL. Fava AM, et al. Expert Opin Biol Ther. 2022 Jan;22(1):7-16. doi: 10.1080/14712598.2022.2005024. Epub 2022 Jan 31. Expert Opin Biol Ther. 2022. PMID: 34757872 Review.
Rilonacept has been evaluated in Phase 2 and 3 clinical trials and was recently approved for RP treatment. AREAS COVERED: This article reviews available clinical trials assessing the efficacy and safety of rilonacept for the treatment of RP. EXPERT OPINION: Findings …
Rilonacept has been evaluated in Phase 2 and 3 clinical trials and was recently approved for RP treatment. AREAS COVERED: This articl …
Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.
Schwier NC. Schwier NC. Ann Pharmacother. 2022 May;56(5):572-581. doi: 10.1177/10600280211036499. Epub 2021 Aug 28. Ann Pharmacother. 2022. PMID: 34459270 Review.
The median time to pain response was 5 days, and median time to normalization of C-reactive protein was 7 days with rilonacept. All patients receiving rilonacept during the run-in period were able to be weaned off of standard background therapy, leading to transitio …
The median time to pain response was 5 days, and median time to normalization of C-reactive protein was 7 days with rilonacept. All p …
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Abbate A, et al. Circ Res. 2020 Apr 24;126(9):1260-1280. doi: 10.1161/CIRCRESAHA.120.315937. Epub 2020 Apr 23. Circ Res. 2020. PMID: 32324502 Free PMC article. Review.
Anakinra also improved outcomes in patients with pericarditis, and it is now considered standard of care as second-line treatment for patients with recurrent/refractory pericarditis. Rilonacept, a soluble IL-1 receptor chimeric fusion protein neutralizing IL-1alpha and IL- …
Anakinra also improved outcomes in patients with pericarditis, and it is now considered standard of care as second-line treatment for patien …
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, Insalaco A, LeWinter M, Lewis BS, Lin D, Luis SA, Nicholls SJ, Pano A, Wheeler A, Paolini JF; RHAPSODY Investigators. Klein AL, et al. N Engl J Med. 2021 Jan 7;384(1):31-41. doi: 10.1056/NEJMoa2027892. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200890 Clinical Trial.
During this period, 2 of 30 patients (7%) in the rilonacept group had a pericarditis recurrence, as compared with 23 of 31 patients (74%) in the placebo group. In the run-in period, 4 patients had adverse events leading to the discontinuation of rilonacept therapy. …
During this period, 2 of 30 patients (7%) in the rilonacept group had a pericarditis recurrence, as compared with 23 of 31 patients ( …
An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.
Campochiaro C, Allanore Y. Campochiaro C, et al. Arthritis Res Ther. 2021 Jun 1;23(1):155. doi: 10.1186/s13075-021-02536-5. Arthritis Res Ther. 2021. PMID: 34074331 Free PMC article. Review.
The drugs studied in phase 1/phase 2 studies included the following: inebilizumab, dabigatran, C-82, pomalidomide, rilonacept, romilkimab, tocilizumab, tofacitinib, pirfenidone, lenabasum, abatacept, belimumab, riociguat, SAR100842 and lanifibranor. ...
The drugs studied in phase 1/phase 2 studies included the following: inebilizumab, dabigatran, C-82, pomalidomide, rilonacept, romilk …
260 results